Aeluma, Inc.ALMU

Aeluma, Inc. markets itself as a pioneer in high-performance compound semiconductors, with platforms spanning mobile, AI, defence, aerospace, robotics, automotive, AR/VR, and-ambitiously-quantum. Its website and press releases trumpet a "large-diameter wafer platform" designed for scalable manufacturing and volume production, positioning the company at the heart of America’s quantum push. The Department of Commerce’s recent announcement of $2 billion in letters of intent for quantum acceleration explicitly names Aeluma among nine companies tapped for leadership, lending the company’s narrative a glossy sheen of official imprimatur. Yet beneath the polished story, the balance sheet tells a different tale: in the quarter ended 31 March 2026, Aeluma booked $1.2 million in revenues and lost $1.8 million, with a diluted EPS of $-0.10.

The company’s cash position remains robust at $37.8 million, a cushion that insulates it from near-term liquidity shocks. But the operating cash flow is negative at $-1.6 million, and R&D spend is running at $882,000, which is less a bet on the future and more a statement of how long the runway really is. The latest 10-Q shows total assets of $42.5 million against liabilities of $2.4 million, leaving shareholders with $40.1 million in equity-hardly a fortune, but enough to keep the lights on while the quantum dream matures.

Aeluma’s technology is framed as "disruptive," but disruption hasn’t yet reached the income statement. The company’s press materials and investor page insist its compound semiconductor platform enables "mass market microelectronics" through partnerships with production-scale foundries, packaging, and integration firms. The evidence supports the claim that Aeluma is embedded in the supply chain, but not that its products have achieved commercial scale or pricing power. The company’s technology page and product images showcase wafer platforms and integration partnerships, yet none of the filings or releases cite customer names, unit volumes, or revenue per customer-details that would substantiate the "large-scale integration" promise.

The quantum commercialisation timeline may have accelerated, but Aeluma’s revenue engine has not. The company’s May 2026 8-K highlights new U.S. contracts, but the 10-Q for the same period offers no breakdown of where those contracts sit-whether in backlog, deferred revenue, or recognised income. Without segment-level disclosure or customer concentration data, investors are left to guess whether the quantum push is already paying rent or merely keeping the lights on.

The stock’s recent trading range-where insiders have been selling shares-sits between $20.54 and $24.74, a band that feels less like a valuation floor and more like a profit-taking corridor. Form 4 filings show insiders disposing of shares in June and July, including 19,900 shares sold on 1 July at prices from $20.54 to $21.52. The weighted average diluted share count now sits at 18.06 billion, a number that grows with each equity-linked event and shrinks any hope of per-share upside without a corresponding rise in earnings.

For those tracking the gap between narrative and numbers, the tension is palpable. Aeluma’s official channels radiate confidence in quantum dominance, but the filings reveal a company still in the investment phase, with a cash cushion, a burn rate, and a long road to monetisation. The question isn’t whether quantum will change the world-it’s whether Aeluma will survive long enough to see the cheque clear.